REPORT ID 4931

Global CD Antigen Cancer Therapy Market Research Report 2017

Publish Date
20-Dec-17
Pages
111
Format
Electronic (PDF)

In this report, the global CD Antigen Cancer Therapy market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of CD Antigen Cancer Therapy in these regions, from 2012 to 2022 (forecast), covering
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
Global CD Antigen Cancer Therapy market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
    AryoGen Biopharma
    Biocad
    Biogen Idec
    Celltrion
    Genentech
    Genmab
    GLYCART Biotechnology
    Hetero Drugs
    mAbxience
    MedImmune
    Merck
    Sandoz
    UCB
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Monoclonal Antibodies
    Antibody-Drug-Conjugates
    Tri-Functional and Bi-Specific T-Cell Engager Antibodies
    Other
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
    Hospitals
    Clinics
    Other

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

Global CD Antigen Cancer Therapy Market Research Report 2017
1 CD Antigen Cancer Therapy Market Overview
    1.1 Product Overview and Scope of CD Antigen Cancer Therapy
    1.2 CD Antigen Cancer Therapy Segment by Type (Product Category)
        1.2.1 Global CD Antigen Cancer Therapy Production and CAGR (%) Comparison by Type (Product Category)(2012-2022)
        1.2.2 Global CD Antigen Cancer Therapy Production Market Share by Type (Product Category) in 2016
        1.2.3 Monoclonal Antibodies
        1.2.4 Antibody-Drug-Conjugates
        1.2.5 Tri-Functional and Bi-Specific T-Cell Engager Antibodies
        1.2.6 Other
    1.3 Global CD Antigen Cancer Therapy Segment by Application
        1.3.1 CD Antigen Cancer Therapy Consumption (Sales) Comparison by Application (2012-2022)
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Other
    1.4 Global CD Antigen Cancer Therapy Market by Region (2012-2022)
        1.4.1 Global CD Antigen Cancer Therapy Market Size (Value) and CAGR (%) Comparison by Region (2012-2022)
        1.4.2 North America Status and Prospect (2012-2022)
        1.4.3 Europe Status and Prospect (2012-2022)
        1.4.4 China Status and Prospect (2012-2022)
        1.4.5 Japan Status and Prospect (2012-2022)
        1.4.6 Southeast Asia Status and Prospect (2012-2022)
        1.4.7 India Status and Prospect (2012-2022)
    1.5 Global Market Size (Value) of CD Antigen Cancer Therapy (2012-2022)
        1.5.1 Global CD Antigen Cancer Therapy Revenue Status and Outlook (2012-2022)
        1.5.2 Global CD Antigen Cancer Therapy Capacity, Production Status and Outlook (2012-2022)

2 Global CD Antigen Cancer Therapy Market Competition by Manufacturers
    2.1 Global CD Antigen Cancer Therapy Capacity, Production and Share by Manufacturers (2012-2017)
        2.1.1 Global CD Antigen Cancer Therapy Capacity and Share by Manufacturers (2012-2017)
        2.1.2 Global CD Antigen Cancer Therapy Production and Share by Manufacturers (2012-2017)
    2.2 Global CD Antigen Cancer Therapy Revenue and Share by Manufacturers (2012-2017)
    2.3 Global CD Antigen Cancer Therapy Average Price by Manufacturers (2012-2017)
    2.4 Manufacturers CD Antigen Cancer Therapy Manufacturing Base Distribution, Sales Area and Product Type
    2.5 CD Antigen Cancer Therapy Market Competitive Situation and Trends
        2.5.1 CD Antigen Cancer Therapy Market Concentration Rate
        2.5.2 CD Antigen Cancer Therapy Market Share of Top 3 and Top 5 Manufacturers
        2.5.3 Mergers & Acquisitions, Expansion

3 Global CD Antigen Cancer Therapy Capacity, Production, Revenue (Value) by Region (2012-2017)
    3.1 Global CD Antigen Cancer Therapy Capacity and Market Share by Region (2012-2017)
    3.2 Global CD Antigen Cancer Therapy Production and Market Share by Region (2012-2017)
    3.3 Global CD Antigen Cancer Therapy Revenue (Value) and Market Share by Region (2012-2017)
    3.4 Global CD Antigen Cancer Therapy Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.5 North America CD Antigen Cancer Therapy Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.6 Europe CD Antigen Cancer Therapy Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.7 China CD Antigen Cancer Therapy Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.8 Japan CD Antigen Cancer Therapy Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.9 Southeast Asia CD Antigen Cancer Therapy Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.10 India CD Antigen Cancer Therapy Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

4 Global CD Antigen Cancer Therapy Supply (Production), Consumption, Export, Import by Region (2012-2017)
    4.1 Global CD Antigen Cancer Therapy Consumption by Region (2012-2017)
    4.2 North America CD Antigen Cancer Therapy Production, Consumption, Export, Import (2012-2017)
    4.3 Europe CD Antigen Cancer Therapy Production, Consumption, Export, Import (2012-2017)
    4.4 China CD Antigen Cancer Therapy Production, Consumption, Export, Import (2012-2017)
    4.5 Japan CD Antigen Cancer Therapy Production, Consumption, Export, Import (2012-2017)
    4.6 Southeast Asia CD Antigen Cancer Therapy Production, Consumption, Export, Import (2012-2017)
    4.7 India CD Antigen Cancer Therapy Production, Consumption, Export, Import (2012-2017)

5 Global CD Antigen Cancer Therapy Production, Revenue (Value), Price Trend by Type
    5.1 Global CD Antigen Cancer Therapy Production and Market Share by Type (2012-2017)
    5.2 Global CD Antigen Cancer Therapy Revenue and Market Share by Type (2012-2017)
    5.3 Global CD Antigen Cancer Therapy Price by Type (2012-2017)
    5.4 Global CD Antigen Cancer Therapy Production Growth by Type (2012-2017)

6 Global CD Antigen Cancer Therapy Market Analysis by Application
    6.1 Global CD Antigen Cancer Therapy Consumption and Market Share by Application (2012-2017)
    6.2 Global CD Antigen Cancer Therapy Consumption Growth Rate by Application (2012-2017)
    6.3 Market Drivers and Opportunities
        6.3.1 Potential Applications
        6.3.2 Emerging Markets/Countries

7 Global CD Antigen Cancer Therapy Manufacturers Profiles/Analysis
    7.1 AryoGen Biopharma
        7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.1.2 CD Antigen Cancer Therapy Product Category, Application and Specification
            7.1.2.1 Product A
            7.1.2.2 Product B
        7.1.3 AryoGen Biopharma CD Antigen Cancer Therapy Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.1.4 Main Business/Business Overview
    7.2 Biocad
        7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.2.2 CD Antigen Cancer Therapy Product Category, Application and Specification
            7.2.2.1 Product A
            7.2.2.2 Product B
        7.2.3 Biocad CD Antigen Cancer Therapy Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.2.4 Main Business/Business Overview
    7.3 Biogen Idec
        7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.3.2 CD Antigen Cancer Therapy Product Category, Application and Specification
            7.3.2.1 Product A
            7.3.2.2 Product B
        7.3.3 Biogen Idec CD Antigen Cancer Therapy Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.3.4 Main Business/Business Overview
    7.4 Celltrion
        7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.4.2 CD Antigen Cancer Therapy Product Category, Application and Specification
            7.4.2.1 Product A
            7.4.2.2 Product B
        7.4.3 Celltrion CD Antigen Cancer Therapy Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.4.4 Main Business/Business Overview
    7.5 Genentech
        7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.5.2 CD Antigen Cancer Therapy Product Category, Application and Specification
            7.5.2.1 Product A
            7.5.2.2 Product B
        7.5.3 Genentech CD Antigen Cancer Therapy Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.5.4 Main Business/Business Overview
    7.6 Genmab
        7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.6.2 CD Antigen Cancer Therapy Product Category, Application and Specification
            7.6.2.1 Product A
            7.6.2.2 Product B
        7.6.3 Genmab CD Antigen Cancer Therapy Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.6.4 Main Business/Business Overview
    7.7 GLYCART Biotechnology
        7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.7.2 CD Antigen Cancer Therapy Product Category, Application and Specification
            7.7.2.1 Product A
            7.7.2.2 Product B
        7.7.3 GLYCART Biotechnology CD Antigen Cancer Therapy Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.7.4 Main Business/Business Overview
    7.8 Hetero Drugs
        7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.8.2 CD Antigen Cancer Therapy Product Category, Application and Specification
            7.8.2.1 Product A
            7.8.2.2 Product B
        7.8.3 Hetero Drugs CD Antigen Cancer Therapy Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.8.4 Main Business/Business Overview
    7.9 mAbxience
        7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.9.2 CD Antigen Cancer Therapy Product Category, Application and Specification
            7.9.2.1 Product A
            7.9.2.2 Product B
        7.9.3 mAbxience CD Antigen Cancer Therapy Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.9.4 Main Business/Business Overview
    7.10 MedImmune
        7.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.10.2 CD Antigen Cancer Therapy Product Category, Application and Specification
            7.10.2.1 Product A
            7.10.2.2 Product B
        7.10.3 MedImmune CD Antigen Cancer Therapy Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.10.4 Main Business/Business Overview
    7.11 Merck
    7.12 Sandoz
    7.13 UCB

8 CD Antigen Cancer Therapy Manufacturing Cost Analysis
    8.1 CD Antigen Cancer Therapy Key Raw Materials Analysis
       8.1.1 Key Raw Materials
       8.1.2 Price Trend of Key Raw Materials
       8.1.3 Key Suppliers of Raw Materials
       8.1.4 Market Concentration Rate of Raw Materials
    8.2 Proportion of Manufacturing Cost Structure
       8.2.1 Raw Materials
       8.2.2 Labor Cost
       8.2.3 Manufacturing Expenses
    8.3 Manufacturing Process Analysis of CD Antigen Cancer Therapy

9 Industrial Chain, Sourcing Strategy and Downstream Buyers
    9.1 CD Antigen Cancer Therapy Industrial Chain Analysis
    9.2 Upstream Raw Materials Sourcing
    9.3 Raw Materials Sources of CD Antigen Cancer Therapy Major Manufacturers in 2015
    9.4 Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders
    10.1 Marketing Channel
        10.1.1 Direct Marketing
        10.1.2 Indirect Marketing
        10.1.3 Marketing Channel Development Trend
    10.2 Market Positioning
        10.2.1 Pricing Strategy
        10.2.2 Brand Strategy
        10.2.3 Target Client
    10.3 Distributors/Traders List

11 Market Effect Factors Analysis
    11.1 Technology Progress/Risk
        11.1.1 Substitutes Threat
        11.1.2 Technology Progress in Related Industry
    11.2 Consumer Needs/Customer Preference Change
    11.3 Economic/Political Environmental Change

12 Global CD Antigen Cancer Therapy Market Forecast (2017-2022)
    12.1 Global CD Antigen Cancer Therapy Capacity, Production, Revenue Forecast (2017-2022)
        12.1.1 Global CD Antigen Cancer Therapy Capacity, Production and Growth Rate Forecast (2017-2022)
        12.1.2 Global CD Antigen Cancer Therapy Revenue and Growth Rate Forecast (2017-2022)
        12.1.3 Global CD Antigen Cancer Therapy Price and Trend Forecast (2017-2022)
    12.2 Global CD Antigen Cancer Therapy Production, Consumption , Import and Export Forecast by Region (2017-2022)
        12.2.1 North America CD Antigen Cancer Therapy Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.2 Europe CD Antigen Cancer Therapy Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.3 China CD Antigen Cancer Therapy Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.4 Japan CD Antigen Cancer Therapy Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.5 Southeast Asia CD Antigen Cancer Therapy Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.6 India CD Antigen Cancer Therapy Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
    12.3 Global CD Antigen Cancer Therapy Production, Revenue and Price Forecast by Type (2017-2022)
    12.4 Global CD Antigen Cancer Therapy Consumption Forecast by Application (2017-2022)

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology/Research Approach
        14.1.1 Research Programs/Design
        14.1.2 Market Size Estimation
        14.1.3 Market Breakdown and Data Triangulation
    14.2 Data Source
        14.2.1 Secondary Sources
        14.2.2 Primary Sources
    14.3 Disclaimer